Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Annexin 1 antibody

An antibody, monoclonal antibody technology, applied in the direction of antibodies, immunoglobulins, antibody medical components, etc.

Inactive Publication Date: 2016-05-18
QUEEN MARY UNIV OF LONDON
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, an often overlooked aspect is the role of Anx-A1 in the adaptive immune response

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Annexin 1 antibody
  • Annexin 1 antibody
  • Annexin 1 antibody

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0078] For the preparation of solutions and elixirs, excipients which may be used include, for example, water, polyols and sugars. For the preparation of suspensions, oils such as vegetable oils may be employed to provide oil-in-water or water-in-oil suspensions.

[0079] Pharmaceutical compositions adapted for transdermal administration may be presented in discrete patches intended to remain in intimate contact with the epidermis of the recipient over an extended period of time. For example, the active ingredient can be released from the patch by iontophoresis as generally described in Pharmaceutical Research, 3(6):318 (1986).

[0080] Pharmaceutical compositions adapted for topical administration can be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils. For infections of the eye or other external tissues such as the mouth and skin, it is preferred to use the composition in the form of a topical ointment or crea...

Embodiment 1-VJ-4

[0139] Example 1 - VJ-4B6 specifically inhibits T cell activation in Annexin-1 containing T cells

[0140] Materials and methods

[0141] mice ( Figure 4B, 5, 6, 7, 8, 9, and 10)

[0142] Balb / C mice were from B&K Universal (Grimston, England). AnxA1 - / - Mice were from the inventor's laboratory, born under sterile conditions at B&K Universal. All mice used in these studies were aged 6-8 weeks. Animal experiments were carried out in accordance with the provisions of the British Home Office Regulations (Guidance on the Operation of Animals, Scientific Procedures Act 1986) and European Union regulations.

[0143] Extraction of mouse T cells ( Figure 4B , 5, 6, 7, 8, 9 and 10 cells used)

[0144] Spleens and lymph nodes (axillary, inguinal, and intestinal) were obtained from 6- to 8-week-old mice and prepared by gentle tissue degradation with a syringe plunger and a 50 μm cell strainer (BD) as previously described. The cell suspension was layered with Ficoll to obtain mo...

Embodiment 2

[0164] The sequencing of embodiment 2-VJ-4B6

[0165]The purpose of this example is to clone the genes of antibody heavy and light chain variable regions from hybridoma cells and to determine the DNA sequence and location of complementarity determining regions (CDRs) and other characteristics.

[0166] Cloning and sequencing of antibody variable regions

[0167] Total RNA was prepared from 1 vial of hybridoma cells using Qiagen RNeasy Mini Kit (CatNo:74104). RNA was eluted with 50 μL of water and checked on a 1.2% agarose gel.

[0168] V H and V K (variable kappa light chain) cDNAs were prepared using reverse transcriptase and primers for IgG and kappa constant regions. First strand cDNAs can be amplified by PCR using a large set of signal sequence primers. Amplified DNAs were purified on silica gel and cloned into vectors TEasy (Promega). Filtered V H and V K clone to confirm that it contains an insert of the appropriate size. The DNA sequence of selected clones wa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
particle sizeaaaaaaaaaa
Login to View More

Abstract

The present invention provides a specific binding molecule produced against the human Anx-A1 protein having the amino acid sequence shown in Figure 2A. The invention also relates to the use of such specific binding molecules in the treatment of T cell mediated diseases.

Description

technical field [0001] The present invention relates to specific binding molecules that bind to annexin-A1 and hybridoma cell lines producing such specific binding molecules, in particular to antibodies and fragments of the molecules. Such specific binding molecules are useful in the treatment of T-cell mediated diseases. Background technique [0002] Glucocorticoids (GCs) are frequently used to treat various chronic autoimmune diseases due to their ability to block both innate and adaptive immune responses. Studies by the present inventors and other research groups over the past 10 years or so have shown that some of the inflammatory effects of GCs on the innate immune response are mediated by a protein called annexin-1 (Anx-A1 ). This protein has been shown to play a role in the homeostatic control of many cell types including neutrophils, macrophages and endothelial cells. However, an often overlooked aspect is the role of Anx-A1 in the adaptive immune response. It is ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/18
CPCA61K2039/505C07K2317/76C07K16/18A61P1/04A61P15/06A61P17/00A61P17/06A61P19/02A61P21/00A61P25/00A61P27/02A61P29/00A61P31/18A61P37/02A61P37/06A61P43/00A61P5/16A61P9/10A61P3/10A61K38/17A61K38/18A61K39/395C07K14/435C07K14/475C07K14/54C07K16/22C07K16/24C07K16/28C07K19/00A61K39/3955A61K45/06
Inventor F·达奎斯托M·佩雷蒂
Owner QUEEN MARY UNIV OF LONDON
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com